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Abstract 
Due to escalating healthcare costs, accurately predicting which patients will incur high costs is an 
important task for payers and providers of healthcare. High-cost claimants (HiCCs) are patients who 
have annual costs above $250,000 and who represent just 0.16% of the insured population but currently 
account for 9% of all healthcare costs. In this study, we aimed to develop a high-performance algorithm 
to predict HiCCs to inform a novel care management system. 
Using health insurance claims from 48 million people and augmented with census data, we applied 
machine learning to train binary classification models to calculate the personal risk of HiCC. To train the 
models, we developed a platform starting with 6,006 variables across all clinical and demographic 
dimensions and constructed over one hundred candidate models.  No requirement regarding 
continuous insurance coverage was imposed on the training and holdout datasets. 
The best model achieved an area under the receiver operating characteristic curve of 91.2%. The model 
exceeds the highest published performance (84%) and remains high for patients with no prior history of 
high-cost status (89%), who have less than a full year of enrollment (87%), or lack pharmacy claims data 
(88%). It attains an area under the precision-recall curve of 23.1%, and precision of 74% at a threshold of 
0.99. A care management program enrolling 500 people with the highest HiCC risk is expected to treat 
199 true HiCCs and generate a net savings of $7.3 million per year.   
Our results demonstrate that high-performing predictive models can be constructed using claims data 
and publicly available data alone, even for rare high-cost claimants exceeding $250,000. Our model 
demonstrates the transformational power of machine learning and artificial intelligence in care 
management, which would allow healthcare payers and providers to introduce the next generation of 
care management programs. 
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Introduction 
It has been known for decades that a relatively small group of patients, termed high-cost claimants 
(HiCCs), accounts for a disproportionate share of healthcare costs and insurance claims [1]. For example, 
members with claims over $50,000 per year represented 1.2% of the U.S. insured population but 
comprised 31% of total spending [2].  In the Medicare population in the U.S., McWilliams and Schwartz 
[3] found that 17% of the population incurred 75% of all costs. In our comprehensive data on the non-
Medicare insured population [4], members with annual costs greater than $250,000 comprise just 0.1% 
of the population yet account for 9% of overall costs. Moreover, in this population the number of HiCCs 
with $250,000 or more has risen by 62% from 36,449 in 2012 to 58,897 in 2016, and the average cost 
was $446,748 per HiCC in 2017. It is therefore not surprising that when asked to list the most important 
strategies for healthcare in the next five years, midsized and large employers ranked managing high-cost 
claimants at the top of the list [5].   
As a population, HiCCs are frequently burdened with multiple chronic diseases, functional limitations, 
and other barriers [6]. Often, high medical expenditures occur as part of acute or invasive therapies that 
are frequently unsuccessful and involve tremendous suffering and disability [7]. Fortunately, there are 
many interventions that could prevent relatively healthy individuals from becoming high-cost claimants 
in the first place [8,9]. An intervention is tailored to a member’s specific circumstances and might consist 
of some combination of a telephone call, additional diagnostic studies, referral to a specialist, digital 
coaching, or other services. Health insurers and providers often maintain a care management 
organization whose role is to identify patients who would benefit from interventions and match them 
with intervention programs (Fig. 1). 
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Figure 1.  The care management process. Members in the covered population are first reviewed by the 
healthcare professional, who, informed by the algorithm, selects some of the members for possible 
intervention.  Selected members are then stratified according to dimensions such as risk and the 
availability of suitable interventions, and if appropriate, receive an intervention.  This referral decision is 
not based solely on the algorithm’s prediction score; rather, the decision is holistic, with the algorithm’s 
prediction score to be considered in the context of the member’s overall clinical situation. The 
intervention is expected to result in some health benefits and cost savings. After the intervention the 
individual returns to the population. 
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Because interventions are costly, potential benefits and cost savings that might result from the 
intervention must be balanced against the cost of the intervention itself [10]. Furthermore, it is 
challenging to determine which individuals would derive the greatest benefit from the intervention, 
even within a narrow subpopulation that has a serious pre-existing condition. Therefore, one of the 
central challenges of a care management program is to identify individuals at risk of acute and expensive 
health outcomes [8].   
The emergence of powerful predictive AI methods seems ideally suited to address this identification 
challenge, since an AI algorithm could potentially predict future costs or medical needs at an individual 
level [11,12].  Such an identification algorithm can then guide limited intervention resources towards 
the highest-risk and highest-need individuals. Therefore, our goal here was to apply machine learning to 
identify members who are at risk of exceeding a total healthcare cost of $250,000 over the next 12 
months. We hypothesized that using a relatively large dataset of insurance claims and a large 
investment in engineering new input variables we could exceed previously published benchmarks in this 
field.  
Overview of existing research   
Much research has examined the problems of predicting medical costs and identifying high-cost 
claimants [12–14]. However, not many studies used very high-cost thresholds, i.e., studies examining 
the top 1% (or higher) of claimants. Additionally, many more studies did not report predictive 
performance in terms of area under the ROC or precision-recall curves, or were descriptive in nature 
rather than predictive; see Table 1.  
Historically, the problem of high-cost claimants was studied by actuarial scientists at the population 
level, with emphasis on parameter estimation and statistical significance tests [15–19]. But with the 
growing availability of data, computing power, and new artificial intelligence and machine learning 
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methods (AI/ML), there has recently been increased interest in predicting costs at the level of the 
individual member instead of estimating parameters for populations [13,20] (for general treatments on 
the contrast between model- and data-driven methods see [21–23]).  
Table 1: Summary of studies that used machine learning methods to identify high-cost claimants. 
Studies were selected by filtering the list of 55 studies in Table 1 of [14], and retaining only those studies 
where the population to be identified was the top 1% or rarer. High-cost claimants above $250,000 have 
a nearly 100-fold lower prevalence than the top 10% of claimants, posing a much greater predictive 
challenge. The only study that reported performance values was [24] (area under the ROC curve, AUC-
ROC: 81%-86%) and all other studies at this high threshold either did not assess predictive modeling 
and/or did not report the AUC-ROC. 
Study   Population to be identified Model/algorithm 
Ash et al. 2001 [25] Top 0.5% Logistic regression 
Coughlin & Long 2010 [26] Top 1%, top 5%, top 10%, 
top 25%, top 50%, and 
bottom 50% 
Descriptive only 
DeLia 2017 [27] Top 1%, top 10%, and 
bottom 90% 
Multinomial probit model 
Hensel et al., 2016 [28] Top 1%, top 2%-5%, top 
6%-50%, bottom 50%, and 
a zero-cost nonuser group 
Logistic regression 
Meenan et al., 2003 [29] Top 0.5% 
 
Risk modeling (linear regression) 
Monheit, 2003 [30] Top 1%, top 5%, top 10%, 
top 20%, top 30%, top 50%, 
and bottom 50% 
 
Logistic regression 
Powers and Chaguturu, 2016 [31] Top 1% Descriptive only 
Riley, 2007 [32] Top 1% and top 5% Descriptive only 
Robst, 2015 [33] Top 1% Logistic regression 
Rosella et al., 2014 [34] Top 1%, top 2-5%, top 6%-
50%, and bottom 50% 
Multinomial logistic regression 
Wammes et al., 2017 [35] Top 1% and top 2%-5% Descriptive only 
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Wodchis et al., 2016 [36] Top 1%, top 5%, top 10%, 
and top 50% 
Descriptive only 
Zhao et al., 2003 [37] Top 0.5% 
 
Linear regression 
 
Detailed review of previous prediction approaches 
A common approach to the problem of predicting high-cost claimants is the use of logistic regression. A 
2010 paper using logistic regression found that inclusion of medical condition information substantially 
improved the prediction of high-cost patients, resulting in "good discrimination" (area under the ROC 
curve, AUC-ROC=0.84%) [38]. The paper also concluded that the number of chronic conditions should be 
considered as a predictor for high-cost prediction models. In a 2015 study, logistic regression was used 
to predict which patients would transition from an intermediate-cost subpopulation to a high-cost 
subpopulation with “reasonable discrimination” (AUC-ROC=0.67%) [39]. Two predictors that were 
significantly associated with high future costs were the count of chronic conditions and having a 
diagnosis of congestive heart failure. In a 2017 paper, a group-based trajectory model based on logistic 
regression was applied to data from a large insurer to accurately predict patients in the highest spending 
trajectory and the top fifth percentile for spending [40]. Using data from the Danish National Health 
Service and Civil Registration System, Tamang et al. implemented a penalized logistic regression model 
with over 1,000 predictors and were able to achieve good predictive performance (AUC-ROC of 0.79%) 
in a “cost bloom analysis” [41]. 
Alternative methods such as machine learning techniques are being applied increasingly to the problem 
of predicting high-cost claimants. Using neural networks, a 2005 study comparing a population model 
against three disease-specific models found that larger cohorts tended to result in a greater predictive 
power of the disease-specific models compared to the population model [42]. A 2013 study using 
routine electronic service records found that a score based on six simple dichotomous questions had 
only “fair” predictive power for health and social care costs in elder patients discharged from acute 
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medical units, with an AUC-ROC of 0.70% [43].  A Canadian group [44] applied machine learning to a 
large range of clinical measurements to identify the top 5% of claimants, attaining an AUC-ROC of 
0.81%-0.94%. In a study where an extended gradient boosting model (XGBoost [45]) was applied on an 
imbalanced dataset from three of the largest health insurers in the U.S., Hartman found that 
oversampling the minority class resulted in better predictive performance (AUC-ROC 0.835) than 
undersampling the majority class [46], at least at the highest thresholds. Gibbs et al. proposed the use of 
asymmetric cost matrices to optimize the threshold for an intervention [10]. 
Whether one uses logistic regression or alternative machine learning techniques, obvious questions 
might be (1) which analytic approaches tend to result in the best predictive performance? and (2) which 
predictors tend to best explain high utilization? A recent review of 55 papers in the literature revealed 
that high utilization was primarily explained by high levels of chronic and mental illness [14]. Another 
2018 literature review concluded that gradient boosting had the best predictive performance overall 
and for low- to medium-cost members, but neural networks and ridge regression had the highest 
performance for high-cost members [13]. 
  
Our contribution 
In this paper, we describe a novel solution to the problem of identifying future high-cost claimants using 
machine learning (ML). We applied one of the largest datasets of healthcare insurance claims (over 50 
million members), achieving one of the highest performance results reported in the literature reviewed 
here. Because health insurance plans typically have access only to their own claims data and not to 
hospital records or specialized registries, we constrained our algorithm to use variables available 
through health insurance claims alone, along with public data on social determinants of health. No 
hospital records or specialized registries were used.  
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Because we anticipated using the predictive model on the full population without any filtering, no 
requirement regarding continuous enrollment in health insurance was imposed on the data. The 
algorithm was therefore designed to operate for members with an incomplete medical history, such as 
less than one year of data. Additionally, the algorithm can function for members for which only medical 
claims and not pharmaceutical claims are available – a situation occurring in approximately 40% of the 
insured population in our data. 
Similar previous studies most often defined HiCCs using thresholds between $50,000 and $100,000 per 
year; some other studies used instead the top 1% to 10% in costs [14]. We instead defined HiCCs as 
members with a yearly total allowed amount that exceeded $250,000: this is the threshold at which 
many reinsurance policies attach. At this threshold, high-cost claimants accounted for about 1.6 out of 
1,000 members, making identification particularly challenging and requiring truly massive datasets. 
Our goal was to identify members who would exceed a total healthcare cost of $250,000 over the next 
12 months. Generally, identification of high-cost claimants is modeled typically as a prediction problem 
in the framework of machine learning. Two formulations are used: (1) predicting cost, namely predicting 
a member’s future dollar cost amount over the next 12 months; or (2) binary classification, namely, 
predicting whether or not a member will exceed a certain cost amount. We evaluated both of these 
formulations and then selected the second formulation (classification) after considering the business 
requirements that are often around a particular threshold and the performance of the models.   
Applying our methods to the problem we found that the best performing model overall was the Light 
Gradient Boosted Trees Classifier (LightGBM) algorithm [47], achieving an AUC-ROC of 91.25% on a 
holdout dataset. This is consistent with the findings of a recent literature review [13], where gradient 
boosting methods had the best predictive performance overall. The model’s AUC-ROC was 7% higher 
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than all previous models at the $250,000 point, and it is estimated that the model’s high performance 
could generate considerable benefits for care management programs. 
Methods  
Construction of input variables 
Our model for predicting health costs was constructed from administrative claims data – the data 
created as part of electronic exchanges between medical facilities, professionals, and pharmacies on the 
one side, and payers on the other. In the U.S. the format of claims data is standardized by HIPAA and 
contains a listing of diagnoses, procedures, drugs, as well as costs. Taken together, claims data provide a 
nearly complete summary of each patient’s medical journey across all types of care. Claims data are 
readily available to all actors in the healthcare system – the medical insurers, government payers, and 
sponsors of healthcare – and are increasingly available to patients. 
The majority of input variables were calculated from claims data over the one-year report period 
4/1/2017 to 3/31/2018, called the “reporting period.” The remaining variables, specifically cost trend 
and some enrollment variables, also included any claims available before the start of the reporting 
period. If no data were available, we assigned null values. The following one-year interval from 4/1/2018 
to 3/31/2019 was considered the “prediction period” and was used to define the high-cost status.  At 
the time of the calculation, claims data were >99% adjudicated. 
Predictors were constructed using SQL (Vertica Analytic Database v8.0.1-3; Micro Focus, Berkshire, 
England, UK). Total allowed amounts for medical conditions (diagnoses) and procedures (services) in the 
current report period were summed using BHI’s Episodes of Care grouper methodology [48]. To prevent 
information leakage, data were processed in an isolated schema that excluded any events occurring 
outside the report period. Indicators of social determinants of health were constructed using publicly 
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available data from the U.S. census, estimated for 2017 American Community Survey (ACS) 5-year 
estimates at the ZIP code level, which were linked to the member based on the member’s ZIP code.  ACS 
data included housing conditions, unemployment, poverty and fraction of the population who are a 
racial minority. 
Table 2 lists the types of variables used in the prediction. The variables were selected by pruning an 
initial list of 6,006 variables, which improved the performance. Feature pruning was performed using a 
feature importance metric available in DataRobot, which implemented a model-agnostic algorithm 
based on permutation testing. We also used a variable importance metric available in DataRobot, which 
captured information about tree splitting in tree-based algorithms. 
TABLE 2. List of the types of input variables. The list of input variables used in the final model were 
selected from a larger list of 6,006 variables. The total number of predictors before and after feature 
selection was 6,006 and 255, respectively. Columns "Original Count” and “Final Count” show the 
number of predictors before and after feature selection, respectively. Details are found in S1 Table. 
Variable Type Group 
Original 
Count 
Final 
Count 
Source Explanation 
Personal Risk 
Factors 
Personal data 32 15 Claims 
Age, gender, family size, 
industry, and others 
Eligibility and 
enrollment 
coverage 
17 5 Claims 
Insurance coverage, e.g., 
number of days a member had 
coverage of a certain type 
Social 
determinants 
of health 
55 39 
Public 
data 
Social vulnerability, education, 
poverty, minority status, 
English-speaking ability, 
housing, transportation, and 
others 
Clinical history 
Procedures, 
diagnoses, and 
drugs 
5,799 100 Claims 
The 12-month cost associated 
with a given procedure, 
diagnosis, or class of drugs 
Clinical events 63 63 Claims 
Groups of ICD-10 and CPT codes 
associated with high cost; count 
of events by type (Emergency 
Department, ambulatory, and 
hospital inpatient) 
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Derived 
indices 
3 3 Claims  
Mortality rate, actuarial life 
expectancy, and years of life lost 
Cost history 
 
Cost indices 26 19 Claims 
Cost over the past 12 and 24 
months, total cost in current 
and past 12 months, cost of 
specialty drugs, days of drug 
supply, and others 
Cost trends 11 11 Claims 
Changes in cost over 12-, six- 
and three-month intervals, 
predicted 12-month cost, cost 
trends, and others 
 
 
Training and holdout population 
The model was trained and tested using realistic data, since we anticipated using the predictive model 
on the entire insured population including individuals with incomplete medical histories. Members were 
required to be enrolled only on the first day of the last month of the reporting period (4/1/2017 to 
3/31/2018) and on the last day of the first month of the predicted period (4/1/2018 to 3/31/2019). No 
requirement regarding continuous enrollment was imposed on the data. In the resulting population, 
63% had both medical and pharmaceutical claims, and 78% had at least one year of continuous 
enrollment. 
Due to limits on the file size for upload to DataRobot, the training dataset was reduced to a 
subpopulation of 3 million members by downsampling the majority class as follows [46]. Due to the high 
threshold of $250,000, HiCCs are rare and therefore each becames very informative. All high-cost 
claimants in the original training dataset were retained. The non-HiCCs in the original training dataset 
were randomly sampled to bring the total complement in the reduced training dataset to 3 million. In 
the final training dataset, the number of HiCCs and non-HiCCs was 61,277 and 2,938,723, respectively, 
and 20% of the training data was used for model selection.  Training of all candidate models was 
completed in 5 hours using a high-performance cluster. 
13 
 
To report on model performance, the final model was evaluated on a holdout dataset of 9,684,279 
members, described in Tables 3 and 4, which was not used in the training. The proportion of high-cost 
claimants (HiCCs) in the holdout reflected the natural proportions in the commercially insured 
population in the US. A small fraction of the population 65 or older is also was included in this 
population.  We reported the performance on all age and gender groups.  Additionally, we further 
stratified the HiCCs into emergent and recurrent, corresponding to individuals with no previous history 
of HiCC status, and those who previously were high-cost claimants. These were, in effect, two distinct 
prediction problems: the emergent population was identified from a very large (N= 48,402,958) set of 
candidates, whereas the recurrent population was identified in a much smaller set (N= 28,249), of which 
approximately 37% became HiCCs in subsequent years. 
TABLE 3.  Shown are demographics of the holdout population used for model evaluation.  
 Population Members HiCCs HiCCs 
 Total holdout 9,684,279 15,051 0.16% 
Gender Female 4,884,419 7,068 0.14% 
 Male 4,799,860 7,983 0.17% 
Age 
group 
0-17 2,066,880 1,085 0.05% 
 18-64 7,389,332 12,490 0.17% 
 65+ 228,067 1,476 0.65% 
HiCC  
history 
Emergent 9,678,645 12,973 0.13% 
 Recurrent 56345,634 2,078 36.9% 
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TABLE 4.  Shown are the highest-cost conditions for HiCCs (same year, top 20 categories ordered by 
number of HiCCs), in the holdout population. * indicates not otherwise specified. 
Highest-cost condition Number of 
members 
Proportion of all 
HiCCs who have the 
condition 
Proportion of all 
members with the 
condition who are 
HiCC 
Cancer* 3,762 1.3% 5.9% 
Coronary artery disease 2,109 0.8% 1.1% 
Pneumonia 1,552 0.6% 1.6% 
Renal failure - acute 1408 0.5% 6.7% 
Heart failure 1,397 0.5% 4.5% 
Renal failure - chronic 1,313 0.5% 11.5% 
Cancer - breast 1,033 0.4% 2.6% 
Sepsis 751 0.3% 4.6% 
Respiratory failure 705 0.3% 5.9% 
Cancer - lung  704 0.3% 13.9% 
Polyneuropathy 534 0.2% 2.4% 
Endocrine disorder* 521 0.2% 1.9% 
Cancer – multiple myeloma 483 0.2% 25.2% 
Cancer – colon* 464 0.2% 5.9% 
Regional enteritis 365 0.1% 1.2% 
Congenital coagulation disease 285 0.1% 10.2% 
Cancer - brain  208 0.1% 11.2% 
Cancer - acquired hemolytic anemia 133 0.05% 13.1% 
Cancer - acute lymphoid leukemia 111 0.04% 10.6% 
Cancer - acute myeloid leukemia 103 0.04% 13.8% 
 
 
 
Machine learning and statistical methods 
BHI uses DataRobot’s predictive platform (DR) version 5.0.1 (DataRobot, Boston, MA).  Our platform 
includes industry-leading tools for exploratory data analysis (EDA), model training, validation, and 
deployment. Once the training data were uploaded, dozens of machine learning models were trained in 
a high-throughput supervised learning system. Training used the log-loss error function and all the 
classifiers have built-in regularization to minimize overfitting in the presence of class imbalances (see 
e.g. [49]). Missing values are extremely rare and were imputed automatically with median values. Data 
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used in model training were stripped of basic HIPAA identifiers and anonymized. We have implemented 
multiple levels of security that governed access to both the models and the results. 
Model selection proceeded in three rounds, where in each round, more data were used (16%, 32%, and 
then 64% of the sample), and the best-performing algorithm in each round was passed on to subsequent 
rounds.  The final round included a grid scan of hyperparameters. The algorithms considered included 
Random Forests, Support Vector Machines, Gradient Boosted Trees, Elastic Nets, Extreme Gradient 
Boosting, and ensembles. Multiple implementations of the algorithms were tested, including the open 
source machine learning libraries from R, scikit-learn, TensorFlow, Vowpal Wabbit, Spark ML, XGBoost, 
and LightGBM.    
Once the automatic selection was complete, we reviewed the model performance on a holdout dataset. 
The top model was selected by reviewing each model holistically, including its predictive performance, 
scoring speed, and interpretability. The model was then subjected to a clinical review and assessment in 
a separate holdout dataset (see below). We found that we could improve the model’s performance by 
pruning variables of lower importance.  We minimized the risk of overfitting by preferring algorithms 
that are inherently resistant to overfitting such as LightGBM, and by confirming that the model’s 
performance was consistent on the training and holdout data. 
Because HiCCs are rare, we used performance metrics that are appropriate for classification problems 
with class imbalances [50,51]: area under the ROC Curve (AUC-ROC) and area under the precision-recall 
curve (AUC-PR).  The AUC-PR has been increasingly suggested as the best overall metric of model 
performance [52], but we used both metrics since most of the existing literature in the field still uses the 
AUC-ROC metric.  We also computed recall (also called sensitivity and true positive rate), precision (also 
called positive predictive value), false positive rate, F1 score, and Matthews correlation coefficient 
(MCC).  In production, we applied isotonic regression to obtain calibrated probability scores [53]. The 
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optimal prediction threshold was normally selected using economic analysis (see below) or in other 
cases, by selecting the score that maximizes the F1 score and the MCC – which agreed within 1% [54].   
The model was deployed both as an API connected to our predictive platform and as an executable Java 
Archive file (JAR), which can be run in any environment supporting Java (e.g., Linux or Windows). The 
consistency of the scores of the two implementations was checked to agree numerically to within 
0.0001. Model validation used JARs containing the model to calculate prediction scores. The running 
time of the JAR model is over 400,000 rows per minute. We applied a stringent development and 
validation process to ensure credibility and accuracy in our recommendations. Our development process 
and model training are very dependent on iterative clinician review and acceptance by clinical staff. 
Also, the internal model validation was conducted by an independent team. 
 
Health economics methods 
Going beyond statistical methods for performance, we estimated the financial and health impact of the 
model.  For this estimation, we placed the model in a typical scenario of a care management program in 
which the model identifies individuals in need of timely interventions [8].  In such a program, individuals 
with the highest model score are evaluated by clinical experts such as nurses, and if appropriate, 
enrolled in an intervention program. We compared the identification model to the common care 
management programs, that often use simple rules to identify members at risk, and therefore have a 
very high false alert rate. 
Because the model is expected to be used in a care management program, the model’s probable 
financial and health impact was assessed in the following care management scenario, which is closely 
based on our data from multiple health insurers in the U.S. In this scenario, one million members are 
covered by the insurer, the rate of HiCCs is 0.16%, and the mean cost per HiCC case is $413,975.  We 
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assumed an intervention program costs $10,000 per member and achieves an average cost reduction of 
15% cost reduction per HiCC.  We conservatively did not attempt to estimate the value of the 
intervention beyond the first year or its effect on non-HiCC members.  The care management program 
has the capacity to treat between 300 and 1000 people per year. The model was considered as a 
replacement for an existing rule-based HiCC identification system, which was assumed to have a 
precision of 2%.  
 
Results  
Our model training found that highest-performing model was a Light Gradient Boosted Trees Classifier 
[47]. The classifier uses 410 trees with a maximum of 16 leaves per tree, boosted at a learning rate of 
0.05, and with no regularization. The three most important predictor variables are age, a tendency for 
rising cost in the last three months of the prediction period, and life expectancy based on actuarial 
tables (see S1 Table).   
When evaluated on the holdout dataset, the algorithm achieves an area under ROC curve of 91.2%, and 
an area under the precision-recall curve of 23.1% (Figure 2).  At a threshold of 0.76 (consistent with the 
highest F1 score), the model gives recall of 33.0% and precision of 29.9% (see Table 5).   
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(A) (B)  
Figure 2: (A) The receiver operating characteristic of the HiCC predictive model is shown. It has an area 
under the ROC curve (AUC-ROC) of 91.2%. The red-dashed diagonal line indicates the chance-level 
performance benchmark. (B) The precision-recall curve of the HiCC predictive model is shown. It has an 
area under the PR curve (AUC-PR) of 23.1%. A red-dashed line just above the X axis indicates the 
reference, i.e., the proportion of high-cost claimants in the holdout data, or 0.16% (cf. TABLE 3). The 
model attains a precision > 80% when high predictive score thresholds are used. 
 
Table 5.  Shown is the performance of the model on the holdout population at various thresholds, 
including the threshold that maximized the F1-Score, 0.76. TP, FP, FN, and TN the number of true 
positives, false positives, false negatives, and true negatives, respectively. Recall is also called true 
positive rate or sensitivity; TNR is true negative rate (also called specificity); precision is also called 
positive predictive value; and NPV is negative predictive value. 
Threshold  TP   FP   FN   TN  Recall TNR Precision NPV 
0.5 6553 28102 8498 9641126 43.54% 99.71% 18.91% 99.91% 
0.6 6025 20930 9026 9648298 40.03% 99.78% 22.35% 99.91% 
0.7 5436 15045 9615 9654183 36.12% 99.84% 26.54% 99.90% 
0.76 4967 11632 10084 9657596 33.00% 99.88% 29.92% 99.90% 
0.8 4606 9405 10445 9659823 30.60% 99.90% 32.87% 99.89% 
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0.9 3258 4049 11793 9665179 21.65% 99.96% 44.59% 99.88% 
1 0 0 15051 9669228 
0.00% 
100.00
% 
N.A. 
99.84% 
 
The following tables (Tables 6 and 7) show the model’s performance in the population of emergent and 
recurrent HiCCs, namely those with and without prior history of HiCC status, respectively.  The AUC of 
the model is higher in the emergent than the recurrent population (89% vs. 81%) and consistent 
between gender and demographic cohorts.  Members that either (1) lacked data on pharmacy benefits 
or (2) lacked one full year of data represented 37% and 22% of the population, respectively, yet the 
model maintained its AUC in these populations to within 1%. 
 
 
TABLE 6. Shown is the model performance in the emergent HiCC population. The threshold for a positive 
class is 0.76, which maximizes the F1 score. AUC is area under the ROC curve; recall is also called true 
positive rate or sensitivity; FPR is false positive rate; precision is also called positive predictive value; and 
NPV is negative predictive value. 
Population AUC N Recall FPR Precision NPV 
National 
population 
88.72% 48,402,958 24.93% 0.11% 16.63% 99.93% 
National prior 
year male 
population 
88.75% 23,989,683 24.68% 0.12% 16.79% 99.93% 
National prior 
year female 
population 
88.62% 24,413,275 25.21% 0.11% 16.45% 99.94% 
National prior 
year age 
group 0-17 
population 
85.28% 10,333,528 22.33% 0.02% 27.09% 99.97% 
National prior 
year age 
87.89% 36,928,635 24.78% 0.12% 16.68% 99.93% 
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group 18-64 
population 
National prior 
year age 
group 65+ 
population 
85.64% 1,140,795 29.16% 0.61% 12.44% 99.79% 
National prior 
year 
pharmacy 
benefit 
population 
89.26% 30,508,394 27.41% 0.13% 16.82% 99.93% 
National prior 
year no 
pharmacy 
benefit 
population 
87.67% 17,894,564 20.05% 0.08% 16.13% 99.94% 
National prior 
year full 
eligibility 
population 
89.03% 37,781,928 24.79% 0.12% 16.10% 99.93% 
National prior 
year lack full 
eligibility 
population 
87.35% 10,621,030 25.48% 0.08% 19.18% 99.94% 
 
 
TABLE 7. Shown is the model performance for the recurrent HiCC population. The threshold for a 
positive class is 0.92, which maximizes the F1 score. AUC is area under the ROC curve; recall is also called 
true positive rate or sensitivity; FPR is false positive rate; precision is also called positive predictive 
value; and NPV is negative predictive value. 
Population AUC N Recall FPR Precision NPV 
National 
population 
81.23% 28,249 83.28% 36.62% 49.98% 89.61% 
National prior 
year male 
population 
81.96% 15,081 83.81% 35.93% 50.84% 89.92% 
National prior 
year female 
population 
80.37% 13,168 82.66% 37.40% 49.00% 89.25% 
National prior 
year age 
group 0-17 
population 
88.18% 4,738 79.14% 19.37% 63.59% 90.04% 
National prior 
year age 
80.15% 21,659 83.91% 39.53% 48.81% 89.33% 
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group 18-64 
population 
National prior 
year age 
group 65+ 
population 
76.95% 1,852 86.56% 46.73% 40.06% 91.66% 
National prior 
year 
pharmacy 
benefit 
population 
81.14% 19,688 84.63% 38.14% 52.38% 89.03% 
National prior 
year no 
pharmacy 
benefit 
population 
80.65% 8,561 79.08% 33.51% 43.37% 90.73% 
National prior 
year full 
eligibility 
population 
80.42% 25,384 84.12% 39.54% 50.06% 88.99% 
National prior 
year lack full 
eligibility 
population 
86.33% 2,865 69.37% 15.39% 48.37% 93.00% 
 
We assessed whether the model possibly under-predicts the number of HiCCs in populations with racial 
minorities and found no evidence for this.  In a univariate analysis correlating the average model score 
in each ZIP code with the ZIP’s fraction of minority population we found a fairly strong positive 
relationship (R2=47%), namely, more HiCC are predicted in areas with higher racial minority.  There was 
no evidence of higher cost in areas of higher racial minority, and indeed the average medical cost 
tended to be slightly lower in these areas ($1.6 lower for every percentage point increase in minority 
status). 
Health economic analysis 
We estimated the financial and health impact of placing the ML algorithm in a typical care management 
program covering a population of 1 million individuals. In the first step of the program, identification, a 
subset of the population is identified as likely future high-cost claimants (Table 8).  In a representative 
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case, the program has the capacity of 1,000 HiCCs, including 500 recurrent (previously known) and 500 
emergent HiCCs, respectively. We set the classification threshold separately for each population and 
calculated that the algorithm would attain precision of 32% and 66% for the emergent and recurrent 
cohorts, respectively. 
Table 8. Shown is the ability of the machine learning algorithm to identify HiCCs for emergent and 
recurrent care management programs.   
 Emergent HiCC program Recurrent HiCC program 
Care management 
program capacity 
Precision True HiCCs Precision True HiCCs 
300 32% 104 66% 200 
500 31% 169 63% 313 
1,000 29% 281 59% 590 
 
To compare the machine learning (ML) algorithm to a conventional rule-based system, we assumed that 
the program has an overall capacity of 500.  The prediction threshold of the algorithm is set to 93% in 
order to generate 500 members with the highest risk scores. At this threshold, the precision was 39.8%, 
producing a population of 199 true HiCCs (Table 9).  By contrast, the rule-based system identified only 
10 true HiCCs, and thus the ML algorithm can impact nearly 20 times as many HiCCs. The cost of the 
program was $5 million in both cases, which translates to a cost per HiCC of $25,125 and $500,000 for 
the ML algorithm and the rule-based system, respectively.  The machine learning-based system would 
result in a net savings of $7.3 million against a net financial cost of $4.4 million for the rule-based 
system. 
Table 9. Shown is the estimated impact of HiCC identification on a typical care management program, 
and comparison of a conventional rule-based system with the current machine learning algorithm. 
 
Rule-based 
system ML algorithm 
Members receiving case management 500  500  
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Care management program cost  $5,000,000  $5,000,000  
Precision 2% 39.8% 
HiCCs benefiting from interventions 10  199  
Program cost per HiCC $500,000 $25,125 
Total savings through care management $620,963 $12,354,536  
Net savings -$4,379,038  $7,354,536  
 
 
Discussion 
Our study describes an algorithm for identification of high-cost claimants at the level of $250,000 per 
year using the methods of machine learning. We demonstrate that using administrative claims with 
census data alone makes it possible to achieve AUC-ROC scores greater than 90%, even though HiCCs 
represent only 0.1% of the commercially insured population in the U.S. These results compare very 
favorably with results published in the literature, which attain performance of 80%-85%, even for 
populations that are easier to identify. This opens an opportunity to make interventions and achieve 
significant cost savings. The performance remains essentially unchanged even in populations with 
limited data, such as partial-year enrollment or lack of drug benefits. 
Unlike previous studies that used a single ML method, we applied a modern parallel machine learning 
platform that considers over 50 models and automatically tuned their hyperparameters. In our 
experience, the best performing non-ensemble models tended to be the eXtreme Gradient Boosting 
algorithm [45] and its derivative, the LightGBM [47]. We also found that ensembling (or blending) of 
models tended to increase performance by 0.2% of AUC-ROC (results not shown here), but these models 
were not adopted because these gains were outweighed by the increase in computational cost and 
because they created certain practical barriers to model deployment. 
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While the literature on predictive models traditionally focuses on AUC-ROC and AUC-PR, in this 
application a more important measure of performance was the precision (also known as PPV) at the 
highest-risk 1,000 members. This is simply due to logistics and the extreme rareness of very high-cost 
claimants. Because the program has a limited enrollment capacity, only the highest-risk HiCCs are 
referred to this program, and the financial and health outcomes are influenced by the precision in this 
elite cohort. 
The model was assessed by considering the model’s precision and recall, combined with the projected 
effectiveness and cost of interventions. We found that in a typical care management program, the ML 
algorithm would create significant health and economic benefits.  When compared to a typical rule-
based system, the algorithm identifies approximately 20 times as many high-cost, high-needs 
individuals, and thus has a nearly 20 times lower cost per case.  The care management program results 
in considerable net savings ($7.3 million) versus a net cost in the rule-based system ($4.3 million). 
Future work could attempt to improve the model further, at the very least by incorporating new 
predictive information. Our experience indicates that claims data are an incredibly rich source of 
information, and we believe that there remain opportunities to improve model performance through 
the synthesis of new predictor variables. Another possibility for improvement might be the inclusion of 
external sources of information from specialty sources, such as credit reporting databases and electronic 
health records. 
 
Limitations and appropriate use of the model 
A general limitation of all predictive methods in practice is that they do not give a prescriptive solution, 
and usually a separate prescriptive methodology is needed for planning interventions for HiCCs, which is 
outside the scope of this work. Common interventions include finding better and cost-efficient 
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healthcare settings, closely monitoring members to control chronic conditions, and others. Many but 
not all members at risk for high costs would be willing or able to receive interventions [8]. 
Multiple efforts have been made to make the trained model free of errors, including quality assurance 
and other good software development life cycle practices. Prediction algorithms need to be regularly 
updated due to rapid changes in the healthcare system, including new treatments or treatment 
pathways and changes in costs. We plan to address these evolving changes by implementing regular 
updates to the training data and the model after deployment. Because our training data contains only 
the U.S. commercially insured population and their dependents, the model’s performance is expected to 
degrade in populations aged 65 or older, or in populations without commercial insurance. We evaluated 
the performance of the model in a variety of populations and found that the degradation is small; 
however, the model should be used with more caution.  
The algorithm presented here is primarily designed to predict the risk of high cost, rather than measures 
of health status or health needs.  Health is known to be systematically different from cost, and 
populations with barriers to healthcare, such as lower socio-economic classes or certain racial 
minorities, have systematically lower healthcare expenditure [55,56].  Furthermore, the algorithm uses 
demographic data such as age, gender, and ZIP code-linked variables in order to maximize its predictive 
performance.  Therefore, the most appropriate use of this model is either in a strictly financial setting, 
or in a holistic care management decision system.  Any use of the predictions should be performed by a 
healthcare professional equipped with rich contextual data because this context would allow the 
healthcare professional to account for contextual information not available to the algorithm, account for 
gaps in the algorithm’s performance, and ensure equitable outcomes.   
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Conclusion 
The predictive model described demonstrates the potential for the next generation of predictive 
algorithms for the healthcare space. High-cost claimants exceeding $250,000 in annual cost account for 
nearly 10% of overall costs but are very rare, representing just 1.6 in every 1,000 members. By using 
hundreds of variables, rich claims data, and modern machine learning, it was possible to train a machine 
learning model that attains an AUC-PR of 91% and a precision of more than 30% in the top 1,000 
members. With the high predictive performance of this model, cost-effective interventions could be 
implemented. 
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Supporting Information 
Table S1. The top 20 input variables of the final model ranked by variable importance. Variable 
importance was calculated based on the weighted number of tree splits and has been normalized so 
that the most important variable (AGE) has a relative importance of 1.  A total of 255 variables were 
used in the final model.  The allowed amount, sometimes simply referred to as cost, is the cost of care 
after the settlement between payers and providers. 
Variable Description Variable 
Importance 
AGE Biological age 1.000 
ALLWD_AMT_FOURTH_3MO_RISING_WV The allowed amount weighted by a linear 
wavelet function rising from 0 to 1 over the 
fourth quarter of the current year 
0.695 
OPTIMAL_LIFE_EXPECTANCY Life expectancy for a healthy person of 
same gender/age based on actuarial tables  
0.653 
PREDICTED_12MO_ALLWD_AMT The output of a submodel estimating the 
allowed amount in the prediction year 
0.595 
YLL_CURRENT_YR Years of life lost in the current year 0.542 
ALLWD_AMT_SECOND_6MO_RISING_WV Similar to above, measuring rising costs in 
the second half of the current year 
0.526 
INPATIENT_DAYS_12MO Number of inpatient days in the current 
year 
0.500 
ANNUAL_ALLWD_AMT_CURRENT_YEAR Summed total allowed amounts from 
inpatient, professional, and pharmacy 
claims for the 12 months in the current 
period, adjusted to reflect 365 days of 
medical coverage 
0.495 
TRG_DAYS_MALIGNANCY The number of days between the most 
recent cancer trigger event and the last 
day in the reporting period 
0.489 
ALLWD_AMT_PRIOR_YEAR The sum allowed amounts from inpatient, 
professional, and pharmacy claims for the 
12 months prior to the current period 
0.489 
TRG_TOTAL_ALLWD_AMT The sum of costs associated with all trigger 
conditions during the reporting period 
0.479 
ALLWD_AMT_FALLING_WV Similar to above, measuring falling costs in 
the current 12 months 
0.463 
ALLWD_AMT_FOURTH_3MO_WV Total allowed amount in the fourth quarter 
of the current year 
0.458 
TOTAL_3_YEAR_ALLWD_AMT Total allowed amount during the 36-month 
period (current reporting period and two 
prior years) 
0.458 
ANNUAL_ALLWD_AMT_PRIOR_YEAR Total cost in the 12 months prior to the 
reporting period, adjusted to reflect 365 
days of medical coverage 
0.442 
MORTALITY_RISK Years of life lost (current year) divided by 
optimal life expectancy 
0.421 
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ALLWD_AMT_RISING_WV Similar to above, measuring rising costs in 
the current 12 months 
0.379 
GPI06_372000 Loop diuretics, not otherwise specified, 
allowed amount over 12 months 
0.368 
ANNUAL_ALLWD_AMT_2_YEARS_PRIOR Total cost in the 12 months prior to the 
reporting period, annualized to reflect 365 
days of medical coverage 
0.368 
DAYS_SINCE_LAST_CLAIM Days since the last available claim 0.363 
 
 
